0
Poster Presentations: Wednesday, October 26, 2011 |

Hypoxia-Induced Pulmonary Hypertension: Synergistic Effects of Sildenafil and Erythropoietin in Mice FREE TO VIEW

Victor Samillan Soto, MD; Colin Schwarzwald, DVM; Thomas Haider, MD; Johannes Vogel, MD; Gassmann Max, DVM; Louise Ostergaard, PhD
Chest. 2011;140(4_MeetingAbstracts):721A. doi:10.1378/chest.1119130
Text Size: A A A
Published online

Abstract

PURPOSE: The term pulmonary arterial hypertension (PAH) describes a group of diseases characterized by elevated pulmonary arterial pressure. The cause can be due to vascular changes, including remodeling in the pre-capillary resistance arterioles. If left untreated, patients might die from right heart failure within an average of three years. Current available treatments may have some clinical benefits but no single therapy can reverse the disease process. The present study was designed to investigate single and combination therapy with erythropoietin (epo) and sildenafil on hypoxia-induced PAH.

METHODS: Mice were randomized, first in a normoxic and a hypoxic group and second to receive saline (control, n=6), epo (n=6), sildenafil (n=6) or epo and sildenafil (n=6). Epo was injected three times per weekly (500 IU/kg) and sildenafil daily (10 mg/kg). The animals were exposed to three weeks of either hypoxia (10 % oxygen) or normoxia, after which they underwent the different treatments for an additional two weeks under the same conditions. Immunohistochemistry was performed to elucidate changes in morphology of pulmonary arterioles and of right heart hypertrophy. Plasma levels of cardiotrophin-1 and atrial natriuretic peptide (ANP) were measured as well as 32 cytokines involved in inflammation and remodeling. Ventilatory parameters were measured using whole body plethysmography.

RESULTS: On average the hypoxic mice lost approximately 20 % of their body weight. This was reduced to 5 % for the group receiving the combination treatment whereas the single treatments showed no effect. The hypoxia-induced increase in right ventricular hypertrophy and medial wall thickness of pulmonary arterioles was significantly attenuated with the combination therapy compared both to the control and to the single treatment groups. Similar results were also observed for cardiotrophin-1 and ANP levels. Animals in the hypoxic group exhibited a deteriorated lung function that could be improved upon treatment. Furthermore, the hypoxia-induced elevated cytokines expression was also attenuated in response to the treatments.

CONCLUSIONS: The combination treatment with epo and sildenafil demonstrated an improvement in the clinical outcome in hypoxia-induced PAH in mice.

CLINICAL IMPLICATIONS: This can provide the basis for future treatment modalities favoring combined epo and sildenafil treatment to potentially improve treatment efficacy.

DISCLOSURE: Gassmann Max: Grant monies (from industry related sources): grant

Louise Ostergaard: Grant monies (from industry related sources): Grant

The following authors have nothing to disclose: Victor Samillan soto, Colin Schwarzwald, Thomas Haider, Johannes Vogel

No Product/Research Disclosure Information

09:00 AM - 10:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543